Skip to content

Study · In vitro (cells) · 2023

3 results

Nicotinamide Mononucleotide Alleviates Angiotensin II-Induced Human Aortic Smooth Muscle Cell Senescence in a Microphysiological Model.

Yin X, Abudupataer M, Ming Y, Xiang B, Lai H, Wang C, Li J, Zhu K

Journal of cardiovascular pharmacology1 Apr 2023Cited by 2 (Europe PMC)

PMID36652727 (opens in a new tab)DOI10.1097/fjc.0000000000001400 (opens in a new tab)PepBankPUB-36652727
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In the HASMC organ-on-a-chip model, NMN pretreatment significantly increased NAD levels.

    In plain wordsIn cells, NMN pretreatment significantly increased NAD levels in an aortic smooth muscle model.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseNAD level
    Study

    humann: not reported in source

    HASMC organ-on-a-chip
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pretreatment with nicotinamide mononucleotide significantly increased the NAD + level and alleviated the senescence of HASMCs, but did not change the expression level of nicotinamide phosphoribosyltransferase.
    1 context sentence
    Summary · context
    We detected cellular senescence markers and NAD + levels in HASMC-based organ-on-a-chip.
  2. 02LabIn vitro (cells)Efficacy outcome

    In the HASMC organ-on-a-chip model, NMN pretreatment alleviated senescence.

    In plain wordsIn cells, NMN pretreatment reduced senescence in an aortic smooth muscle model.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseHASMC senescence
    Study

    humann: not reported in source

    HASMC organ-on-a-chip
    Outcome group
    Aging markers · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pretreatment with nicotinamide mononucleotide significantly increased the NAD + level and alleviated the senescence of HASMCs, but did not change the expression level of nicotinamide phosphoribosyltransferase.
    1 context sentence
    Summary · context
    We detected cellular senescence markers and NAD + levels in HASMC-based organ-on-a-chip.
  3. 03LabIn vitro (cells)Mechanism

    In the HASMC organ-on-a-chip model, NMN pretreatment did not change nicotinamide phosphoribosyltransferase expression.

    In plain wordsIn cells, NMN pretreatment did not change nicotinamide phosphoribosyltransferase expression in an aortic smooth muscle model.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeNicotinamide phosphoribosyltransferase expression
    Study

    humann: not reported in source

    HASMC organ-on-a-chip
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pretreatment with nicotinamide mononucleotide significantly increased the NAD + level and alleviated the senescence of HASMCs, but did not change the expression level of nicotinamide phosphoribosyltransferase.
    1 context sentence
    Summary · context
    We detected cellular senescence markers and NAD + levels in HASMC-based organ-on-a-chip.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.